HGCO19 vaccine candidate: Gennova starts enrolment for Phase 1/2 human clinical trials

The DBT said it has approved additional funding towards clinical studies of India's first of its kind' mRNA-based COVID-19 vaccine, HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2QnXUOb
via IFTTT